Potentials of alginate-containing drugs in pediatric practice
Abstract
The aim of review. Basing on analysis of clinical studies carried out in Russia and abroad, devoted to evaluation of efficacy and safety of alginate-containing of drugs, to demonstrate mechanisms of their effect and potential of application in pediatric practice.
Original positions. Prevalence of gastroesophageal reflux disease (GERD) among different age groups necessitates development of new approaches to its treatment. Comparative characteristic and specificity of antacid, antisecretory and alginate-containing drugs action at treatment of GERD at adult patients, pregnant women and children of various age as mono- and combined therapy is presented. Mechanisms and features of effect of drugs Gaviscon and Gaviscon-forte are discussed. Significant safety and confirmed efficacy of alginatecontaining drugs was demonstrated at various clinical symptoms of GERD at children from the 2-weeks age, pregnant women at the second and third trimesters of pregnancy and at adult patients. Data of instrumental investigations, including esophagogastroduodenoscopy and 24-hour intraesophageal pH-metry, showing statistically significant positive effect of these drugs are presented.
Conclusion. Antireflux, cytoprotective, prokinetic and sorption properties of Gaviscon and Gavisconforte along with absence of any significant undesirable effects, proves feasibility of their application at treatment of GERD, including pediatric practice both as monotherapy and within combined treatment modes, in relation to severity of clinical manifestations.
About the Authors
S. I. ErdesRussian Federation
B. O. Matsukatova
Russian Federation
Ye. M. Mukhametova
Russian Federation
References
1. Губергриц Н.Б. Применение маалокса в гастроэнтерологической практике // Сучасна гастроэнтерология. – 2002. – № 2. – С. 55–59.
2. Исаков В.А. Эпидемиология ГЭРБ: Восток и Запад // Эксп. клин. гастроэнтерол. – 2004. – № 5 (спецвыпуск). – С. 2–6.
3. Пахомова И.Г, Ткаченко Е.И., Успенский Ю.П. Первый опыт использования «Гевискона» в лечении ГЭРБ // Рус. мед. журн. – 2007. – Т. 15, № 22. – С. 1–4.
4. Приворотский В.Ф., Луппова Н.Е. Кислотозависимые заболевания у детей (клиническая картина, диагностика, лечение): Учебн. пособие. – 2-е изд. – СПб: «СПбМАПО», 2005.
5. Ткаченко Е.И., Успенский Ю.П. На чем основываются перспективы использования Гевискона – нового для России альгинатсодержащего препарата – в лечении кислотозависимых заболеваний органов пищеварения // Эксп. клин. тер. гастроэнтерол. – 2007. – № 4. – С. 41–46.
6. Успенский Ю.П., Барышникова Н.В., Пахомова И.Г. Клинические перспективы использования препаратов на основе альгиновой кислоты в лечении ГЭРБ // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2009. – Т. 19, № 2. – С. 79–84.
7. Циммерман Я.С. Хронический гастрит и язвенная болезнь. – Пермь: Изд. Мед. академии, 2000. – 256 с.
8. Beckloff G.L., Chapman J.H., Shiverdecker P. Objective evaluation of an antacid with unusual properties // J. Clin. Pharmacol. – 1972. – Vol. 12, N 1. – P. 11–21.
9. Buts J.P., Barudi C., Otte J.B. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24-h continuous pH monitoring in infants and children // Eur. J. Pediatr. – 1987. – Vol. 146, N 2. – P. 158.
10. Caster D.O., Brunton S.A., Earnest D.L. et al. Management algorithms for the primary care physician and the specialist // Pract. Gastroenterol. – 1998. – Vol. 18. – P. 46.
11. Cho Y.S., Choi M.G, Jeong J.J. et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea // Am. J. Gastroenterol. – 2005. – Vol. 100, N 4. – P. 747–753.
12. Davies N.M., Farr S.J., Kellaway I.W. et al. A comparison of the gastric retention of alginate containing tablet formulations with and without the inclusion of excipient calcium ions // Int. J. Pharm. – 1994. – Vol. 105. – P. 97–101.
13. Fonkalsrud E.W., Ament M.E. Gastroesophageal reflux in childhood // Curr. Probl. Surg. – 1996. – Vol. 33, N 1. – P. 1–70.
14. Friedman C., Shriver R., Burnham D., Mandel K.G. Comparison of cimetidine 100, 200 or 300 mg in preventing meal-induced heartburn // J. Gastroenterol. Hepatol. – Vol. 12. – P. 206.
15. Greally P., Hampton F.J., MacFadyen U.M., Simpson H. Gaviscon and Carobel compared with cisapride in gastroesophageal reflux // Arch. Dis. Child. – 1992. – Vol. 67, N 5. – P. 618–621.
16. Jones R., Lydeard S. Prevalence of symptoms of dyspepsia in the community // Lancet. – 1989. – N 1. – P. 47–51.
17. Kahrilas P.J. Gastroesophageal reflux disease and its complications // Sleisenger and Fordtran’s Gastrointestinal and Liver Disease / Eds. M. Feldman et al. – 6th ed. – New York: W.B. Saunders, 1997. – Vol. 1. – P. 498–517.
18. Knight L.C., Maurer A.H., Ammar I.A. et al. Use of 111In-labeled alginate to study the pH dependence of alginic acid anti-esophageal reflux barrier // Int. J. Rad. Appl. Instrum. (B). – 1988. – Vol. 15. – P. 563–571.
19. Knudsen A., Lebech M., Hansen M. Upper gastrointestinal symptoms in the third trimester of the normal pregnancy // Eur. J. Obstet. Gynecol. Reprod. Biol. – 1995. – Vol. 60, N 1. – P. 29–33.
20. Lang G.D., Dougall A. Comparative study of Algicon suspension and magnesium trisilicate mixture in the treatment of reflux dyspepsia of pregnancy // Br. J. Clin. Pract. – 1990. – Vol. 66. – P. 48–51.
21. Le Luyer B., Mougenot J.F., Mashako L. et al. Multicenter study of sodium alginate in the treatment of regurgitation in infants //Ann. Pediatr. (Paris). – 1992. – Vol. 39, N 10. – P. 635–640.
22. Lundell L. Advances in treatment strategies for gastroesophageal reflux disease: EAGE Postgraduate Course. – Geneva, 2002. – P. 13–22.
23. Mann S.G., Gottrel J., Murakam A. et al. Prevention of heartburn relapse by low-dose famotidine: a test mael model for duration of symptom control // Aliment. Pharmacol. Ther. – 1997. – Vol. 11. – P. 121–127.
24. May H.A., Wilson C.G., Hardy J.G. Monitoring radiolabeled antacid preparations in the stomach // Int. J. Pharm. – 1984. – Vol. 19. – P. 169–176.
25. McDowell R.H. Properties of Alginates. – London: Alginate Industries Ltd., 1968. – 42 p.
26. Miller S. Comparison of the efficacy and safety of a new aluminium-free pediatric alginate preparation and placebo in infants with recurrent gastroesophageal reflux // Curr. Med. Res. Opin. – 1999. – Vol. 15, N 3. – P. 160–168.
27. Oderda G., Dell’Olio D., Forni M. et al. Treatment of childhood peptic esophagitis with famotidine or alginate-antacid // Ital. J. Gastroenterol. – 1990. – Vol. 22, N 6. – P. 346–349.
28. Poynard T. Relapse rate of patients after healing of esophagitis – a prospective study of alginate as self-care treatment for 6 months // Aliment. Pharmacol. Ther. – 1993. – Vol. 7, N 4. – P. 385–392.
29. Sandmark S., Zenk I. New principles in the treatment of reflux esophagitis in hiatal hernia // Svenska Lakartidningen. – 1964. – Vol. 61. – P. 1940–1944.
30. Sontag S., Robinson M., McCallum R.W. et al. Ranitidine therapy for gastroesophageal reflux desease. Results of large double-blind trial // Arch. Intern. Med. – 1987. – Vol. 147, N 10. – P. 1485–1491.
31. Sookoo A., Saggu P.S., Wollen N. A double-blind, randomized, multicentre, parallel group, phase III study in 90 patients with recurrent gastroesophageal reflux comparing the efficacy and safety of Gaviscon Infant (minus aluminium) with placebo // LMK. – 1996. – Vol. 3. – P. 26–34.
32. Spechler S.J. Epidemiology of gastroesophageal history of gastroesophageal reflux disease // Digestion. – 1992. – Vol. 51 (suppl. 1). – P. 24–29.
33. Uzan M., Uxan S., Surean C., Richard-Berthe C. Heartburn and regurgitation in pregnancy, efficacy and innocuousness of treatment with Gaviscon suspension // Rev. Fr. Gynecol. Obstet. – 1988. – Vol. 83. – P. 569–572.
34. Van der Meer S.B., Forget P.P., Kuijten R.H., Arends J.W. Gastroesophageal reflux in children with recurrent abdominal pain // Acta Paediatr. – 1992. – Vol. 81, N 2. – P. 137–140.
35. Von Hutt H.J., Tauber O., Flach D. Gaviscon in the treatment of reflux disease. Results of an observational study // Fortschr. Med. – 1990. – Vol. 108. – P. 598–600.
36. Weldon A.P., Robinson M.J. Trial of Gaviscon in the treatment of gastroesophageal reflux in infancy // Aust. Paediatr. J. – 1972. – Vol. 8. – P. 279–281.
37. Williams D.L., Haigh G.G., Redfern J.N. The symptomatic treatment of reflux heartburn and dyspepsia with liquid Gaviscon: a multicentre general practitioner study // J. Int. Med. Res. – 1979. – Vol. 7. – P. 551–555.
Review
For citations:
Erdes S.I., Matsukatova B.O., Mukhametova Ye.M. Potentials of alginate-containing drugs in pediatric practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(5):55-60. (In Russ.)
Views:
13
Email this article 
